Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) – Stock analysts at SVB Leerink lifted their Q2 2022 earnings per share (EPS) estimates for Cullinan Oncology in a report issued on Monday, May 16th. SVB Leerink analyst A. Berens now forecasts that the company will post earnings of $5.44 per share for the quarter, up from their prior estimate of $5.25. SVB Leerink currently has a “Outperform” rating on the stock. SVB Leerink also issued estimates for Cullinan Oncology’s FY2022 earnings at $3.65 EPS.
Other equities analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Cullinan Oncology in a report on Tuesday. Zacks Investment Research upgraded Cullinan Oncology from a “sell” rating to a “hold” rating and set a $12.00 price objective for the company in a research note on Monday.
Cullinan Oncology (NASDAQ:CGEM – Get Rating) last announced its earnings results on Monday, May 16th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.34.
A number of institutional investors have recently modified their holdings of CGEM. Nextech Invest AG purchased a new position in Cullinan Oncology during the 4th quarter worth $18,842,000. State Street Corp grew its position in Cullinan Oncology by 223.8% during the 4th quarter. State Street Corp now owns 1,175,363 shares of the company’s stock worth $18,136,000 after purchasing an additional 812,404 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Cullinan Oncology by 72.9% in the third quarter. BlackRock Inc. now owns 1,629,594 shares of the company’s stock valued at $36,780,000 after acquiring an additional 687,316 shares in the last quarter. Foresite Capital Opportunity Management V LLC purchased a new stake in shares of Cullinan Oncology in the fourth quarter valued at about $5,879,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Cullinan Oncology by 80.8% in the third quarter. Geode Capital Management LLC now owns 421,238 shares of the company’s stock valued at $9,507,000 after acquiring an additional 188,316 shares in the last quarter. 93.62% of the stock is currently owned by institutional investors.
In related news, major shareholder Vision Scs F2 sold 35,158 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $11.23, for a total transaction of $394,824.34. Following the completion of the sale, the insider now owns 1,305,873 shares in the company, valued at approximately $14,664,953.79. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Bvf Partners L. P/Il acquired 276,000 shares of the stock in a transaction on Friday, April 1st. The shares were acquired at an average cost of $10.75 per share, for a total transaction of $2,967,000.00. Following the completion of the transaction, the insider now directly owns 301,671 shares in the company, valued at approximately $3,242,963.25. The disclosure for this purchase can be found here. 21.78% of the stock is currently owned by company insiders.
About Cullinan Oncology (Get Rating)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- The Weber, Inc Growth Story Goes Up In Smoke
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.